Zura Bio Limited Class A Ordinary Shares Earnings

The next earnings date for Zura Bio Limited Class A Ordinary Shares has not yet been scheduled.

Analyst Estimates of Zura Bio Limited Class A Ordinary Shares Earnings

No Results.
Report DateEstimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Zura Bio Limited Class A Ordinary Shares Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
05/08/2025---$-0.19-19.80%
11/07/2024---$-0.26-116.67%
08/13/2024---$-0.17-13.33%
05/09/2024Before Market$-0.0291.30%
03/28/2024Before Market$-0.1917.39%
11/13/2023Before Market$-0.1828.00%
08/14/2023Before Market$-1.31-424.00%
05/31/2023---$-2.76---
03/28/2023---$0.04---
11/14/2022---$0.03---
08/12/2022---$0.13---
04/11/2022---$0.05---
11/19/2021---$0.35---
08/27/2021---$0---

More About Zura Bio Limited Class A Ordinary Shares

Country
USA
Full Time Employees
30

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Zura Bio Limited Class A Ordinary Shares Earnings” Can Refer to the Zura Bio Limited Class A Ordinary Shares Earnings Date

Some people say “Zura Bio Limited Class A Ordinary Shares earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Zura Bio Limited Class A Ordinary Shares position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Zura Bio Limited Class A Ordinary Shares Stock on the Earnings Date

If you own Zura Bio Limited Class A Ordinary Shares stock (ZURA) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Zura Bio Limited Class A Ordinary Shares might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Zura Bio Limited Class A Ordinary Shares shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Zura Bio Limited Class A Ordinary Shares Earnings

You can contact us any time if you would like to ask questions about Zura Bio Limited Class A Ordinary Shares earnings or anything else related to the stock market.